Axa S.A. Buys 71,796 Shares of Edwards Lifesciences Corporation $EW

Axa S.A. raised its stake in Edwards Lifesciences Corporation (NYSE:EW) by 11.1% during the second quarter, HoldingsChannel.com reports. The fund owned 716,907 shares of the medical research company’s stock after purchasing an additional 71,796 shares during the quarter. Axa S.A.’s holdings in Edwards Lifesciences were worth $56,069,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also made changes to their positions in EW. Brighton Jones LLC purchased a new stake in shares of Edwards Lifesciences in the fourth quarter worth about $266,000. Headlands Technologies LLC bought a new stake in Edwards Lifesciences in the 1st quarter worth approximately $48,000. Zions Bancorporation National Association UT purchased a new stake in shares of Edwards Lifesciences during the 1st quarter worth approximately $68,000. Townsquare Capital LLC boosted its position in shares of Edwards Lifesciences by 33.0% during the 1st quarter. Townsquare Capital LLC now owns 8,649 shares of the medical research company’s stock valued at $627,000 after acquiring an additional 2,148 shares during the last quarter. Finally, Invesco Ltd. grew its holdings in shares of Edwards Lifesciences by 2.6% in the first quarter. Invesco Ltd. now owns 4,287,712 shares of the medical research company’s stock valued at $310,773,000 after purchasing an additional 107,241 shares in the last quarter. Institutional investors own 79.46% of the company’s stock.

Wall Street Analyst Weigh In

EW has been the topic of a number of recent research reports. Wells Fargo & Company reaffirmed an “overweight” rating and set a $96.00 price target (up previously from $95.00) on shares of Edwards Lifesciences in a research note on Friday. The Goldman Sachs Group set a $104.00 target price on shares of Edwards Lifesciences and gave the company a “buy” rating in a research report on Friday, October 31st. Raymond James Financial raised shares of Edwards Lifesciences from a “market perform” rating to an “outperform” rating and set a $96.00 price target for the company in a report on Monday, November 3rd. Wall Street Zen cut Edwards Lifesciences from a “strong-buy” rating to a “buy” rating in a research note on Monday, September 29th. Finally, Robert W. Baird raised their price objective on Edwards Lifesciences from $83.00 to $88.00 and gave the company a “neutral” rating in a research note on Friday, December 5th. Three research analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating, ten have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $93.09.

Insiders Place Their Bets

In other news, VP Daniel J. Lippis sold 1,020 shares of Edwards Lifesciences stock in a transaction on Monday, November 10th. The stock was sold at an average price of $82.55, for a total transaction of $84,201.00. Following the completion of the sale, the vice president directly owned 22,002 shares in the company, valued at approximately $1,816,265.10. This trade represents a 4.43% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Scott B. Ullem sold 7,700 shares of the business’s stock in a transaction on Tuesday, December 9th. The shares were sold at an average price of $84.47, for a total transaction of $650,419.00. Following the sale, the chief financial officer directly owned 39,898 shares of the company’s stock, valued at $3,370,184.06. This represents a 16.18% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders sold 21,720 shares of company stock worth $1,814,660. Insiders own 0.34% of the company’s stock.

Edwards Lifesciences Stock Down 1.3%

Shares of NYSE EW opened at $83.18 on Wednesday. The company has a debt-to-equity ratio of 0.06, a current ratio of 4.00 and a quick ratio of 3.29. The company has a market cap of $48.27 billion, a P/E ratio of 35.86, a PEG ratio of 3.79 and a beta of 0.97. Edwards Lifesciences Corporation has a 1 year low of $65.94 and a 1 year high of $87.89. The firm has a 50-day simple moving average of $81.19 and a two-hundred day simple moving average of $78.88.

Edwards Lifesciences (NYSE:EW) last released its earnings results on Thursday, October 30th. The medical research company reported $0.67 EPS for the quarter, beating analysts’ consensus estimates of $0.59 by $0.08. Edwards Lifesciences had a return on equity of 14.70% and a net margin of 23.25%.The firm had revenue of $1.55 billion for the quarter, compared to analysts’ expectations of $1.49 billion. During the same quarter in the prior year, the firm posted $0.67 earnings per share. The company’s quarterly revenue was up 14.7% on a year-over-year basis. Edwards Lifesciences has set its FY 2025 guidance at 2.560-2.620 EPS and its Q4 2025 guidance at 0.580-0.640 EPS. Research analysts anticipate that Edwards Lifesciences Corporation will post 2.45 earnings per share for the current year.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.